-
Je něco špatně v tomto záznamu ?
What Is the Significance of Variant Histology in Urothelial Carcinoma
N. Lobo, SF. Shariat, CC. Guo, MI. Fernandez, W. Kassouf, A. Choudhury, J. Gao, SB. Williams, MD. Galsky, JA. Taylor, M. Roupret, AM. Kamat
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- karcinom z přechodných buněk klasifikace diagnóza patologie terapie MeSH
- lidé MeSH
- prognóza MeSH
- urologické nádory klasifikace diagnóza patologie terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
CONTEXT: Urothelial carcinoma can exhibit a wide range of variant morphologies. Many variants present diagnostic challenges and carry clinical implications that inform prognosis and treatment decisions. OBJECTIVE: To provide an overview of the diagnostic, therapeutic, and prognostic significance of histological variants of urothelial carcinoma. EVIDENCE ACQUISITION: A PubMed/MEDLINE-based literature search was conducted using the key terms "urothelial carcinoma", "variant histology", "nested", "micropapillary", "microcystic", "sarcomatoid", "squamous differentiation", "glandular differentiation", "clear cell", "plasmacytoid", "lymphoepithelioma-like carcinoma", "squamous cell carcinoma", "small cell carcinoma", "adenocarcinoma", "radiotherapy", "neoadjuvant chemotherapy", and "adjuvant chemotherapy". EVIDENCE SYNTHESIS: The incidence of variant histology is increasing due to improved recognition. Nonetheless, diagnosis can pose challenges due to sampling limitations and interobserver variability. Although associated with advanced disease at presentation, survival outcomes for most variants do not differ significantly compared with pure urothelial carcinoma of the same stage. Controversy exists regarding optimal management due to the low quality of available evidence. For most cases, radical cystectomy with pelvic lymph node dissection (with neoadjuvant chemotherapy when appropriate) represents the standard of care. Small cell carcinoma and lymphoepithelioma-like carcinoma appear to be particularly chemosensitive. CONCLUSIONS: Accurate identification of variant histological subtypes is an important part of risk stratification, as these variants exhibit aggressive biological behaviour. Variant histology tumours are associated with advanced disease at presentation, which must be considered when counselling patients regarding survival outcomes. Optimal management remains to be defined but in most cases; neoadjuvant chemotherapy and radical cystectomy with pelvic lymph node dissection remains the mainstay of treatment. PATIENT SUMMARY: It is important to recognise histological variants of urothelial carcinoma as they indicate aggressive disease. When compared with patients with pure urothelial carcinoma of the same disease stage, survival does not appear to be significantly worse. In most cases, patients with invasive variant histology should be treated with neoadjuvant chemotherapy and radical cystectomy. Take Home Messages Accurate identification of variant histology is important as it exhibits aggressive biological behaviour and affects treatment. Although associated with advanced disease at presentation, with appropriate treatment, survival outcomes are not significantly different compared with pure urothelial carcinoma of the same stage.
Department of Pathology University of Texas MD Anderson Cancer Center Houston TX USA
Department of Surgery McGill University Health Center Montreal Canada
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Clínica Alemana de Santiago Chile
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Frimley Health NHS Foundation Trust Frimley Camberley UK
Department of Urology Hôpital Pitié Salpêtrière Paris France
Department of Urology University of Kansas Medical Centre Kansas City KS USA
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology The University of Texas Medical Branch Galveston TX USA
Faculty of Medicine Clínica Alemana Universidad del Desarrollo Santiago Chile
GRC n°5 ONCOTYPE URO Sorbonne Université AP HP Paris France
Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York NY USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020352
- 003
- CZ-PrNML
- 005
- 20210830102048.0
- 007
- ta
- 008
- 210728s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euf.2019.09.003 $2 doi
- 035 __
- $a (PubMed)31530497
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Lobo, Niyati $u Department of Urology, Frimley Health NHS Foundation Trust, Frimley, Camberley, UK
- 245 10
- $a What Is the Significance of Variant Histology in Urothelial Carcinoma / $c N. Lobo, SF. Shariat, CC. Guo, MI. Fernandez, W. Kassouf, A. Choudhury, J. Gao, SB. Williams, MD. Galsky, JA. Taylor, M. Roupret, AM. Kamat
- 520 9_
- $a CONTEXT: Urothelial carcinoma can exhibit a wide range of variant morphologies. Many variants present diagnostic challenges and carry clinical implications that inform prognosis and treatment decisions. OBJECTIVE: To provide an overview of the diagnostic, therapeutic, and prognostic significance of histological variants of urothelial carcinoma. EVIDENCE ACQUISITION: A PubMed/MEDLINE-based literature search was conducted using the key terms "urothelial carcinoma", "variant histology", "nested", "micropapillary", "microcystic", "sarcomatoid", "squamous differentiation", "glandular differentiation", "clear cell", "plasmacytoid", "lymphoepithelioma-like carcinoma", "squamous cell carcinoma", "small cell carcinoma", "adenocarcinoma", "radiotherapy", "neoadjuvant chemotherapy", and "adjuvant chemotherapy". EVIDENCE SYNTHESIS: The incidence of variant histology is increasing due to improved recognition. Nonetheless, diagnosis can pose challenges due to sampling limitations and interobserver variability. Although associated with advanced disease at presentation, survival outcomes for most variants do not differ significantly compared with pure urothelial carcinoma of the same stage. Controversy exists regarding optimal management due to the low quality of available evidence. For most cases, radical cystectomy with pelvic lymph node dissection (with neoadjuvant chemotherapy when appropriate) represents the standard of care. Small cell carcinoma and lymphoepithelioma-like carcinoma appear to be particularly chemosensitive. CONCLUSIONS: Accurate identification of variant histological subtypes is an important part of risk stratification, as these variants exhibit aggressive biological behaviour. Variant histology tumours are associated with advanced disease at presentation, which must be considered when counselling patients regarding survival outcomes. Optimal management remains to be defined but in most cases; neoadjuvant chemotherapy and radical cystectomy with pelvic lymph node dissection remains the mainstay of treatment. PATIENT SUMMARY: It is important to recognise histological variants of urothelial carcinoma as they indicate aggressive disease. When compared with patients with pure urothelial carcinoma of the same disease stage, survival does not appear to be significantly worse. In most cases, patients with invasive variant histology should be treated with neoadjuvant chemotherapy and radical cystectomy. Take Home Messages Accurate identification of variant histology is important as it exhibits aggressive biological behaviour and affects treatment. Although associated with advanced disease at presentation, with appropriate treatment, survival outcomes are not significantly different compared with pure urothelial carcinoma of the same stage.
- 650 _2
- $a karcinom z přechodných buněk $x klasifikace $x diagnóza $x patologie $x terapie $7 D002295
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a urologické nádory $x klasifikace $x diagnóza $x patologie $x terapie $7 D014571
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- 700 1_
- $a Guo, Charles Chuanhai $u Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 700 1_
- $a Fernandez, Mario I $u Department of Urology, Clínica Alemana de Santiago, Chile; Faculty of Medicine, Clínica Alemana Universidad del Desarrollo, Santiago, Chile
- 700 1_
- $a Kassouf, Wassim $u Department of Surgery (Urology), McGill University Health Center, Montreal, Canada
- 700 1_
- $a Choudhury, Ananya $u Manchester Cancer Research Centre, Division of Cancer Science, School of Medical Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
- 700 1_
- $a Gao, Jianjun $u Division of Cancer Medicine, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 700 1_
- $a Williams, Stephen B $u Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA
- 700 1_
- $a Galsky, Matthew D $u Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 700 1_
- $a Taylor, John A $u Department of Urology, University of Kansas Medical Centre, Kansas City, KS, USA
- 700 1_
- $a Roupret, Morgan $u GRC n°5, ONCOTYPE-URO, Sorbonne Université, AP-HP, Paris, France; Department of Urology, Hôpital Pitié-Salpêtrière, Paris, France
- 700 1_
- $a Kamat, Ashish M $u Division of Surgery, Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org
- 773 0_
- $w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 6, č. 4 (2020), s. 653-663
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31530497 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102048 $b ABA008
- 999 __
- $a ok $b bmc $g 1691012 $s 1140798
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 6 $c 4 $d 653-663 $e 20190915 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
- LZP __
- $a Pubmed-20210728
